Default company panoramic image
41939e0b 35ac 4a05 b558 3c46fcd136d7

Tyrosine Pharma, Inc.

Every 40 seconds someone in the US suffers from stroke. Tyrosine Pharma is in development of a therapeutic treatment to reduce brain damage.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Albuquerque, NM, USA
  • Currency USD
  • Founded January 2013
  • Employees 2
  • Website

Company Summary

Dr. Surojit Paul, the product's inventor, has developed a method and formula to generate a cell-permeable STEP peptide that can bind constitutively to its substrates and is resistant to degradation. Preliminary studies have indicated that intravenous injection of the cell-permeable STEP peptide either before or after an acute ischemic stroke can provide significant protection against ischemic brain injury. ​


  • Default avatar
    Wayne Laslie

    Former Chief Operating Officer of Myriad Genetics & Myrexis. Over 30 years experience in Pharmaceutical commercialization

  • Default avatar
    Alan Kolod

    Former CFO of the Future Medical Systems Group (Switzerland). 30+ years in financial management and growing companies and leading them to positive exits.

  • Default avatar
    Dr. Surojit Paul

    PhD in Neurosciences. Tenured Professor at University of New Mexico Health Sciences Center

  • Default avatar
    Adrian Hobden
    Board Member

    Adrian is a successful pharmaceutical executive with a storied career that started with Glaxo Smith Kline and also included his role as the President of the Pharmaceutical Division of publicly-traded Myriad Genetics and CEO of publicly-traded Myrexis, Inc. a drug development company focused on cancer therapeutics. Adrian is a graduate of Cambridge University in the United Kingdom (UK) and holds a PhD degree in molecular biology from the Universi


  • Default avatar
    Peacock & Meyers (IP), Candice Lee Owens (Corporate)
    Default avatar
    Thad Porch (Porch CPAs)

Previous Investors

  • Default avatar
    New Mexico Angels
    Default avatar